Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
vasopressin analog |
| gptkbp:approvedBy |
gptkb:European_Union
gptkb:United_States |
| gptkbp:ATCCode |
H01BA04
|
| gptkbp:CASNumber |
14636-12-5
|
| gptkbp:contraindication |
pregnancy
ischemic heart disease |
| gptkbp:discoveredBy |
gptkb:Ferring_Pharmaceuticals
|
| gptkbp:eliminationHalfLife |
40 minutes
|
| gptkbp:hasMolecularFormula |
C52H74N16O15S2
|
| https://www.w3.org/2000/01/rdf-schema#label |
Terlipressin
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
vasoconstriction
|
| gptkbp:pregnancyCategory |
contraindicated
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
abdominal pain
headache hypertension bradycardia |
| gptkbp:synonym |
Glypressin
Triglycyl-lysine vasopressin |
| gptkbp:UNII |
Y39E4KEP1J
|
| gptkbp:usedFor |
treatment of bleeding esophageal varices
treatment of hepatorenal syndrome |
| gptkbp:yearOfUSApproval |
2022
|
| gptkbp:bfsParent |
gptkb:H01CB02
|
| gptkbp:bfsLayer |
6
|